• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169445 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
. Y. T$ w1 Y; c* O0 X$ [3 K" Y5 E( ]

/ D/ T+ G; [. v* m( Y; d3 kSub-category:
4 `% M$ X: q$ T( A0 `& |% b( v6 NMolecular Targets : h7 G" I9 _, t: i  v% Z  f3 O

* U" D0 r! B3 }7 L- h, D
5 X# ?0 w$ X2 K  X1 QCategory:2 x2 @) z2 @& A% S' S) \
Tumor Biology 7 x! M3 D. e6 p) |. ^

0 L- t( b0 ?( |# `' S# W' \( W0 w, @- S4 I9 x' u9 u
Meeting:5 t! ~3 P, f$ y* {# o5 |
2011 ASCO Annual Meeting
. i# g' N3 `* t0 M: G( `* S, L6 [2 k6 L. R- H) I- ~3 R0 L9 Y

8 B3 b8 m" G2 `Session Type and Session Title:; V, ]* N& u* M
Poster Discussion Session, Tumor Biology
4 X2 ?9 h* L6 f1 m( ~& u
$ H, T3 t7 `5 E, D4 ~6 J3 r) |2 B
Abstract No:* B5 I( Z% E( K
10517 ! Q* X5 R+ D- u/ n, N# c* N
# f; e" R2 h6 v, O# F# `/ |
3 J8 I; M3 M+ h( c" T: D/ B$ M) k
Citation:4 R* F/ P8 L; b0 y
J Clin Oncol 29: 2011 (suppl; abstr 10517) 6 C* q6 X" D" `3 a& C% K
2 G4 B# u' L  V5 i; m. L

1 K+ H: Y8 W1 A* gAuthor(s):8 Y+ q8 J# Q- I4 D0 G2 k6 `4 ~
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 1 Z4 E9 ]3 i" g9 i: ]- u
6 j/ o5 }3 \4 J4 X7 i# U6 j
( s' }0 L/ T8 s
  R3 U( d9 x! N" L& X
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.( z) I+ Q  S, u9 `3 I" P+ x
- }; B7 Q5 D6 H
Abstract Disclosures
& c9 ?) m5 U7 C; H- D% h6 u) t7 {) R% S9 ^* ?
Abstract:* e+ k9 \* P. k. b0 Q
8 B( f7 |/ P2 I: C" F7 A
* r" v! l+ c0 u/ n" P
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
$ o# U% f8 z% f0 P- R( g3 ^4 n; y* G; ^" u3 @

; C3 k  ~( e/ f" d% s1 H6 h2 p$ R
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
7 p; F) Y6 K& ?+ {$ T, v没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
* j: w/ t' o6 i  o
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
9 U$ U7 v) B; J' ]易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
9 q* [5 q* j1 K0 ~4 sALK一个指标医院要900多 ...
2 x3 N1 I. P5 G! n, `
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
& N! g& S1 U6 v/ B6 [( N6 w( d# G7 \7 h; @. G6 L, L; G  `
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表